

Douglas G Mcneel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7885316/douglas-g-mcneel-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

114
papers

3,398
citations

34
h-index

54
g-index

120
ext. papers

3,913
ext. citations

5.7
avg, IF

5.45
L-index

#	Paper	IF	Citations
114	GM-CSF elicits antibodies to tumor-associated proteins when used as a prostate cancer vaccine adjuvant.. <i>Cancer Immunology, Immunotherapy</i> , 2022 , 1	7.4	0
113	Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon β -mediated suppression of immune checkpoint receptor expression.. <i>Oncolimmunology</i> , 2022 , 11, 2054758	7.2	1
112	Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors 2021 , 9,		2
111	Optimizing Flow Cytometric Analysis of Immune Cells in Samples Requiring Cryopreservation from Tumor-Bearing Mice. <i>Journal of Immunology</i> , 2021 , 207, 720-734	5.3	0
110	PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy. <i>Oncolimmunology</i> , 2021 , 10, 1912892	7.2	5
109	Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 ,	6.2	4
108	Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 5162-5171	12.9	8
107	Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 562-573	9.7	21
106	Androgen deprivation as a tumour-immunomodulating treatment. <i>Nature Reviews Urology</i> , 2020 , 17, 371-372	5.5	
105	Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages 2020 , 8,		3
104	Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Cancers</i> , 2020 , 12,	6.6	1
103	Infectious Tolerance as Seen With 2020 Vision: The Role of IL-35 and Extracellular Vesicles. <i>Frontiers in Immunology</i> , 2020 , 11, 1867	8.4	4
102	Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3507-3517	2.2	19
101	FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab 2019 , 7, 23		15
100	Noninvasive Imaging and Quantification of Radiotherapy-Induced PD-L1 Upregulation with Zr-Df-Atezolizumab. <i>Bioconjugate Chemistry</i> , 2019 , 30, 1434-1441	6.3	20
99	Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 1661-1669	7.4	12
98	Heterologous vaccination targeting prostatic acid phosphatase (PAP) using DNA and vaccines elicits superior anti-tumor immunity dependent on CD4+ T cells elicited by DNA priming. <i>Oncolimmunology</i> , 2018 , 7, e1456603	7.2	8

97	Therapeutic Cancer Vaccines: How Much Closer Are We?. <i>BioDrugs</i> , 2018 , 32, 1-7	7.9	11
96	Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine 2018 , 6, 21		20
95	Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 110-120	8.8	73
94	Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. <i>Oncotarget</i> , 2018 , 9, 25586-25596	3.3	48
93	A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2018 , 24, 1525-1535	12.9	95
92	Immunological considerations underlying heat shock protein-mediated cancer vaccine strategies. <i>Immunology Letters</i> , 2018 , 193, 1-10	4.1	7
91	TLR Stimulation during T-cell Activation Lowers PD-1 Expression on CD8 T Cells. <i>Cancer Immunology Research</i> , 2018 , 6, 1364-1374	12.5	19
90	Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD). <i>Prostate</i> , 2017 , 77, 812-821	4.2	4
89	DNA vaccines for prostate cancer. <i>Pharmacology & Therapeutics</i> , 2017 , 174, 27-42	13.9	25
88	DNA Vaccines 2017 , 183-198		
87	Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8 T Cells. <i>Cancer Immunology Research</i> , 2017 , 5, 630-641	12.5	35
86	ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer. <i>Molecular Pharmaceutics</i> , 2017 , 14, 1782-1789	5.6	62
85	Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells. <i>Cancer Immunology Research</i> , 2017 , 5, 1074-1085	12.5	12
84	Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination 2017 , 5, 56		7
83	Androgen deprivation and immunotherapy for the treatment of prostate cancer. <i>Endocrine-Related Cancer</i> , 2017 , 24, T297-T310	5.7	47
82	Preclinical Pharmacokinetics and Biodistribution Studies of ⁸⁹ Zr-Labeled Pembrolizumab. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 162-168	8.9	110
81	DNA vaccine with pembrolizumab to elicit antitumor responses in patients with metastatic, castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 168-168	2.2	6
80	Preclinical and clinical development of DNA vaccines for prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 193-204	2.8	28

79	Immunotherapy for prostate cancer: False promises or true hope?. <i>Cancer</i> , 2016 , 122, 3598-3607	6.4	19
78	Mini-intronic plasmid vaccination elicits tolerant LAG3 CD8 T cells and inferior antitumor responses. <i>OncolImmunology</i> , 2016 , 5, e1223002	7.2	9
77	B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines. <i>Oncotarget</i> , 2016 , 7, 67903-67918	3.5	14
76	Inducible expression of cancer-testis antigens in human prostate cancer. <i>Oncotarget</i> , 2016 , 7, 84359-84374	3.4	14
75	SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer. <i>Oncotarget</i> , 2016 , 7, 50997-51011	3.3	6
74	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma 2016 , 4, 92		25
73	Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. <i>OncolImmunology</i> , 2016 , 5, e1165377	7.2	38
72	Molecular Imaging of Immunotherapy Targets in Cancer. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1487-1498	2.9	65
71	PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. <i>Cancer Immunology Research</i> , 2015 , 3, 946-55	12.5	57
70	Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). <i>Human Vaccines and Immunotherapeutics</i> , 2015 , 11, 2469-74	4.4	22
69	Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4500-4500	2.2	10
68	Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 3692-704	12.9	33
67	DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses. <i>Vaccine</i> , 2014 , 32, 1707-15	4.1	14
66	A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T. <i>Cancer Immunology Research</i> , 2014 , 2, 988-995	12.5	40
65	DNA Vaccines 2014 , 1-16		
64	Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5012-5012	2.2	24
63	Engineering DNA Vaccines for Cancer Therapy 2014 , 449-471		
62	Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination 2013 , 1, 2		2

61	The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 585-96	7.4	21
60	A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 407-15	3.3	11
59	Long-term immune responses elicited by a DNA vaccine encoding prostatic acid phosphatase (PAP) in patients with nonmetastatic castrate-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 135-135	2.2	1
58	Prostate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatments. <i>Chinese Clinical Oncology</i> , 2013 , 2,	2.3	1
57	Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. <i>Journal of Immunology</i> , 2012 , 189, 5590-601	5.3	82
56	Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence. <i>Expert Review of Vaccines</i> , 2012 , 11, 1315-7	5.2	28
55	Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. <i>Prostate</i> , 2012 , 72, 487-98	4.2	13
54	Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes. <i>Prostate</i> , 2012 , 72, 730-40	4.2	6
53	T cells localized to the androgen-deprived prostate are TH1 and TH17 biased. <i>Prostate</i> , 2012 , 72, 1239-47.	4.2	16
52	Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 1137-47	7.4	73
51	Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response. <i>Oncolmmunology</i> , 2012 , 1, 1546-1556	7.2	9
50	Vaccination using peptides spanning the SYT-SSX tumor-specific translocation. <i>Expert Review of Vaccines</i> , 2012 , 11, 1401-4	5.2	6
49	DNA Vaccines for Prostate Cancer. <i>Current Cancer Therapy Reviews</i> , 2012 , 8, 254-263	0.4	8
48	Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells. <i>Journal of Immunotherapy</i> , 2011 , 34, 569-80	5	27
47	CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 781-92	7.4	20
46	Pilot trial of interleukin-2 and zoledronic acid to augment Γ cells as treatment for patients with refractory renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 1447-60	7.4	92
45	Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancer. <i>Prostate</i> , 2011 , 71, 134-46	4.2	10
44	Sipuleucel-T: immunotherapy for advanced prostate cancer. <i>Open Access Journal of Urology</i> , 2011 , 3, 49-60		4

43	Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. <i>Cancer Research</i> , 2011 , 71, 6785-95	10.1	47
42	IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy. <i>Journal of Biomedicine and Biotechnology</i> , 2011 , 2011, 454861		12
41	Identification of autoantibodies in a patient with testicular cancer and concurrent inflammatory bowel disease. <i>Journal of Clinical Oncology</i> , 2010 , 28, e680-3	2.2	1
40	Reply to M.R. Smith et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e59-e59	2.2	
39	The SSX family of cancer-testis antigens as target proteins for tumor therapy. <i>Clinical and Developmental Immunology</i> , 2010 , 2010, 150591		71
38	Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. <i>Human Immunology</i> , 2010 , 71, 496-504	2.3	67
37	DNA vaccines for the treatment of prostate cancer. <i>Expert Review of Vaccines</i> , 2010 , 9, 731-45	5.2	25
36	DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. <i>Journal of Immunotherapy</i> , 2010 , 33, 639-47	5	94
35	HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 943-53	7.4	38
34	Prioritization of cancer antigens: keeping the target in sight. <i>Expert Review of Vaccines</i> , 2009 , 8, 1657-61	5.2	13
33	Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. <i>Clinical Cancer Research</i> , 2009 , 15, 3406-15	12.9	34
32	Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. <i>Cancer Research</i> , 2009 , 69, 609-15	10.1	211
31	Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4047-54	2.2	193
30	An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans. <i>Journal of Clinical Investigation</i> , 2009 , 119, 2031-41	15.9	33
29	His-tag ELISA for the detection of humoral tumor-specific immunity. <i>BMC Immunology</i> , 2008 , 9, 23	3.7	7
28	Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer. <i>Prostate</i> , 2007 , 67, 1729-39	4.2	25
27	Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. <i>Prostate</i> , 2007 , 67, 1781-90	4.2	42
26	Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 885-95	7.4	42

25	Endothelin receptor antagonists in cancer therapy. <i>Cancer Investigation</i> , 2007 , 25, 785-94	2.1	52
24	Prostate cancer immunotherapy. <i>Current Opinion in Urology</i> , 2007 , 17, 175-81	2.8	20
23	MAD-CT-2 identified as a novel melanoma cancer-testis antigen using phage immunoblot analysis. <i>Journal of Immunotherapy</i> , 2007 , 30, 675-83	5	12
22	GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2007 , 7, 1893-902	5.4	41
21	Cellular immunotherapies for prostate cancer. <i>Biomedicine and Pharmacotherapy</i> , 2007 , 61, 315-22	7.5	9
20	Effects of a monoclonal anti-alpha3beta1 integrin antibody on blood vessels - a pharmacodynamic study. <i>Investigational New Drugs</i> , 2007 , 25, 49-55	4.3	30
19	Immunotherapy for prostate cancer - recent progress in clinical trials. <i>Clinical Advances in Hematology and Oncology</i> , 2007 , 5, 465-74, 477-9	0.6	6
18	New approaches to identification of antigenic candidates for future prostate cancer immunotherapy. <i>Update on Cancer Therapeutics</i> , 2006 , 1, 273-284		4
17	Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). <i>Vaccine</i> , 2006 , 24, 293-303	4.1	45
16	Identification of autoantibodies elicited in a patient with prostate cancer presenting as dermatomyositis. <i>International Journal of Urology</i> , 2006 , 13, 211-7	2.3	21
15	Humoral immune responses to testis antigens in sera from patients with prostate cancer. <i>Cancer Immunity</i> , 2006 , 6, 1		32
14	A phase I study of a DNA vaccine targeting prostatic Acid phosphatase in patients with stage D0 prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2005 , 4, 215-8	3.3	11
13	Antigen-specific IgG elicited in subjects with prostate cancer treated with flt3 ligand. <i>Journal of Immunotherapy</i> , 2005 , 28, 268-75	5	16
12	Immune-based therapies for prostate cancer. <i>Immunology Letters</i> , 2005 , 96, 3-9	4.1	21
11	Phase I trial of a monoclonal antibody specific for alpha3beta1 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. <i>Clinical Cancer Research</i> , 2005 , 11, 7851-60	12.9	129
10	Prostate cancer antigens and vaccines, preclinical developments. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2005 , 22, 247-61		11
9	Identification of antigen-specific IgG in sera from patients with chronic prostatitis. <i>Journal of Clinical Immunology</i> , 2004 , 24, 492-502	5.7	44
8	Newer therapies in advanced prostate cancer. <i>Clinical Prostate Cancer</i> , 2004 , 3, 150-6		25

7	Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant. <i>Journal of Clinical Immunology</i> , 2003 , 23, 62-72	5.7	42
6	Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens. <i>Immunobiology</i> , 2003 , 207, 179-86	3.4	24
5	Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. <i>Prostate</i> , 2001 , 47, 222-9	4.2	50
4	Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. <i>Breast Cancer Research and Treatment</i> , 2000 , 62, 245-52	4.4	127
3	ANTIBODY IMMUNITY TO PROSTATE CANCER ASSOCIATED ANTIGENS CAN BE DETECTED IN THE SERUM OF PATIENTS WITH PROSTATE CANCER. <i>Journal of Urology</i> , 2000 , 164, 1825-1829	2.5	61
2	Immunization With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor as a Vaccine Adjuvant Elicits Both a Cellular and Humoral Response to Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor. <i>Blood</i> , 1999 , 93, 2653-2659	2.2	35
1	Immunization With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor as a Vaccine Adjuvant Elicits Both a Cellular and Humoral Response to Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor. <i>Blood</i> , 1999 , 93, 2653-2659	2.2	4